InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INM InMed Pharmaceuticals Inc

Post-Mkt 02-24 17:49:02 EST

0.8800

+0.0300

+3.53%

盘后0.9000

+0.0200+2.27%

16:38 EST

High0.9000	Low0.8496	Vol59.97K
Open0.8500	D1 Closing0.8500	Amplitude5.93%
Mkt Cap2.57M	Tradable Cap1.31M	Total Shares2.92M
T/O53.33K	T/O Rate4.04%	Tradable Shares1.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INM","market":"US","secType":"STK","nameCN":"InMed Pharmaceuticals Inc","latestPrice":0.88,"timestamp":1771966800000,"preClose":0.85,"halted":0,"volume":59969,"hourTrading":{"tag":"盘后","latestPrice":0.9,"preClose":0.88,"latestTime":"16:38 EST","volume":4350,"amount":3644.3600954999997,"timestamp":1771969117487,"change":0.02,"changeRate":0.022727,"amplitude":0.002727},"delay":0,"changeRate":0.03529411764705886,"floatShares":1484000,"shares":2919186,"eps":-2.88,"marketStatus":"Post-Mkt","change":0.03,"latestTime":"02-24 17:49:02 EST","open":0.85,"high":0.9,"low":0.8496,"amount":53329.01883035999,"amplitude":0.059294,"askPrice":0.9095,"askSize":15,"bidPrice":0.8798,"bidSize":49,"shortable":3,"etf":0,"ttmEps":-2.88,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771981200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.85,"preHourTrading":{"tag":"盘前","latestPrice":0.88,"preClose":0.85,"latestTime":"08:34 EST","volume":10,"amount":8.8,"timestamp":1771940042359,"change":0.03,"changeRate":0.035294,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.9,"preClose":0.88,"latestTime":"16:38 EST","volume":4350,"amount":3644.3600954999997,"timestamp":1771969117487,"change":0.02,"changeRate":0.022727,"amplitude":0.002727},"volumeRatio":2.071869},"requestUrl":"/m/hq/s/INM","defaultTab":"news","newsList":[{"id":"2610706942","title":"InMed Pharmaceuticals Inc. Q2 BayMedica revenue drops 26% to USD 0.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2610706942","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610706942?lang=en_us&edition=fundamental","pubTime":"2026-02-12 19:04","pubTimestamp":1770894246,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDLYYmmc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2610910964","title":"InMed Pharma Q4 R&D expenses USD 0.63 million, down 30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610910964","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610910964?lang=en_us&edition=fundamental","pubTime":"2026-02-12 06:05","pubTimestamp":1770847513,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. reported its results for the quarter ended December 31, 2025. For the Pharma segment, research and development expenses were USD 0.63 million for the quarter, marking a 30 percentage point decrease. General and administrative expenses totaled USD 1.32 million, a decrease of 3 percentage points. Amortization and depreciation expenses were USD 0.05 million, reflecting a 2 percentage point decrease. During the period, InMed advanced its INM-901 program, completing the first preclinical study with the oral formulation administered in large animals. These results will guide the design of a planned human Phase 1 clinical trial. The company also completed additional chemistry, manufacturing, and controls development to scale up the INM-901 manufacturing process in preparation for Investigational New Drug enabling studies and regulatory interactions with the FDA. Revenue for the company is derived from manufacturing and distribution sales of bulk rare cannabinoid pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL8hWlBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2592947515","title":"InMed Pharmaceuticals Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592947515","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592947515?lang=en_us&edition=fundamental","pubTime":"2025-12-18 09:01","pubTimestamp":1766019665,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. held its annual general and special meeting of shareholders on December 17, 2025. Shareholders approved the election of the board of directors and the appointment of CBIZ CPAs P.C. as auditors for the following year. Approval was also granted for the potential issuance of 20% or more of the company's common shares pursuant to the Standby Equity Purchase Agreement with YA II PN, Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile  on December 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL9J0pkw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2591647203","title":"ADVISORY-Dated alerts on InMed Pharmaceuticals withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2591647203","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591647203?lang=en_us&edition=fundamental","pubTime":"2025-12-15 23:05","pubTimestamp":1765811124,"startTime":"0","endTime":"0","summary":"ADVISORY-Dated alerts on InMed Pharmaceuticals withdrawnAlerts published on InMed Pharmaceuticals INM.O expecting the H.R. 5371 Act to have a negative impact on its unit Baymedica were dated and have ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2591480642","title":"InMed Pharmaceuticals Inc - Expects Negative Impact on Baymedica From New Act H.r. 5371 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2591480642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591480642?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:37","pubTimestamp":1765809436,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL0AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2591642942","title":"BayMedica Faces Uncertainty as New Law Threatens Commercial Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642942","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591642942?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:33","pubTimestamp":1765809187,"startTime":"0","endTime":"0","summary":"BayMedica, InMed Pharmaceuticals Subsidiary, Faces Material Impact from New Legislation. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL1VyMW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2584814511","title":"Why Did Vivakor Shares Surge 17% After Hours?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584814511","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584814511?lang=en_us&edition=fundamental","pubTime":"2025-11-20 16:55","pubTimestamp":1763628900,"startTime":"0","endTime":"0","summary":"Vivakor shares jumped 17% in after-hours trading after the company reported widening losses and rising interest expenses.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/20/Market-Prudence-To-Increase-Amid-Growing.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/20/Market-Prudence-To-Increase-Amid-Growing.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/11/48969121/why-did-vivakor-shares-surge-17-after-hours","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48969121/why-did-vivakor-shares-surge-17-after-hours","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["INM","BK4144","BK4120","BK4007","VIVK"],"gpt_icon":0},{"id":"2584183421","title":"What's Driving InMed's (INM) 22% After-Hours Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584183421","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584183421?lang=en_us&edition=fundamental","pubTime":"2025-11-20 15:28","pubTimestamp":1763623737,"startTime":"0","endTime":"0","summary":"InMed shares jumped 22% in after-hours trading after the company reported encouraging large-animal study results for its Alzheimer&#39;s drug candidate INM-901.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48968515/whats-driving-inmeds-inm-22-after-hours-surge","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM","GLP","BK4590","BK4144"],"gpt_icon":0},{"id":"2584979338","title":"InMed Pharmaceuticals Completes Key Study for INM-901","url":"https://stock-news.laohu8.com/highlight/detail?id=2584979338","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584979338?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:51","pubTimestamp":1763589103,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals ( ($INM) ) just unveiled an announcement. On November 18, 2025, InMed Pharmaceuticals announced the successful completion of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-completes-key-study-for-inm-901?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-completes-key-study-for-inm-901?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2584893095","title":"InMed Completes Key Pharmacokinetic Studies for Alzheimer’s Candidate INM-901","url":"https://stock-news.laohu8.com/highlight/detail?id=2584893095","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584893095?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:14","pubTimestamp":1763471651,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals ( ($INM) ) has provided an update. InMed Pharmaceuticals announced the successful completion of pharmacokinetic studies for i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inmed-completes-key-pharmacokinetic-studies-for-alzheimers-candidate-inm-901?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inmed-completes-key-pharmacokinetic-studies-for-alzheimers-candidate-inm-901?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2584932967","title":"InMed Pharmaceuticals Completes Large Animal Study for Alzheimer's Drug Candidate INM-901","url":"https://stock-news.laohu8.com/highlight/detail?id=2584932967","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584932967?lang=en_us&edition=fundamental","pubTime":"2025-11-18 20:31","pubTimestamp":1763469066,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. announced the successful completion of pharmacokinetic studies in large animal models for its Alzheimer's disease candidate, INM-901. The company reported that the oral formulation of INM-901 demonstrated a favorable bioavailability profile and achieved anticipated therapeutic levels of systemic exposure over a seven-day dosing period. Neurological assessments found no adverse neural or behavioral effects. These results, which have already been obtained, will support the design and planning of first-in-human clinical trials. InMed is preparing for a pre-IND meeting with the FDA and advancing further studies to support an IND submission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL2hFfTp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2581445045","title":"InMed Pharmaceuticals reports $1.1 million in BayMedica revenues for Q1 fiscal 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2581445045","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581445045?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:51","pubTimestamp":1762465916,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. reported cash and cash equivalents of $9.3 million as of September 30, 2025, down from $11.1 million at the end of June 2025. Short-term investments were $42.9 thousand, and accounts receivable totaled $343.5 thousand. Inventories stood at $890.8 thousand. General and administrative expenses were $1.5 million for the three months ended September 30, 2025, and are expected to remain stable for the remainder of fiscal 2026. Research and development expenses decreased due to reduced spending on external contractors and compensation but are anticipated to increase as preclinical and IND-enabling work on lead program INM-901 advances. The company expects available cash to fund planned operations into the fourth quarter of calendar year 2026. Business developments include progress toward clinical readiness for INM-901, a small-molecule therapy targeting multiple pathways associated with Alzheimer's disease, and the addition of two new directors to the board.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9qKrrK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2578652899","title":"InMed Pharmaceuticals Inc. Announces Date for Upcoming Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2578652899","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578652899?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:55","pubTimestamp":1761339326,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has announced that it will hold its annual general and special meeting of shareholders virtually on December 17, 2025. Shareholders will have the opportunity to vote on key matters relating to the company. The management information circular with detailed information about the meeting and the matters to be addressed is available on the company's website, as well as through regulatory filings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL8pR5Ng:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2578547730","title":"InMed Pharmaceuticals Files Amendment to Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2578547730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578547730?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:06","pubTimestamp":1761336368,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has filed an amendment to its annual report on Form 10-K/A for the fiscal year ended June 30, 2025. The amendment includes information previously omitted from the original filing, specifically Items 10, 11, 12, 13, and 14 of Part III of Form 10-K, as the company will not file a definitive proxy statement within the required timeframe. Additionally, new certifications from the principal executive officer and principal financial officer have been filed as exhibits. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL94bp2w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2577587295","title":"InMed Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for Director John Steven Bathery","url":"https://stock-news.laohu8.com/highlight/detail?id=2577587295","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577587295?lang=en_us&edition=fundamental","pubTime":"2025-10-24 07:32","pubTimestamp":1761262320,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names John Steven Bathery as a director and the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL7V4pKc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2576093471","title":"InMed Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for Director Neil Klompas","url":"https://stock-news.laohu8.com/highlight/detail?id=2576093471","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576093471?lang=en_us&edition=fundamental","pubTime":"2025-10-18 08:34","pubTimestamp":1760747661,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Neil A. Klompas as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251018:nNDL58XHnG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"gpt_icon":0},{"id":"2575874646","title":"InMed Pharmaceuticals Appoints John Bathery to Board of Directors; Bryan Baldasare to Step Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2575874646","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575874646?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:31","pubTimestamp":1760617875,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has appointed John Bathery to its Board of Directors, effective immediately. Bathery brings over 30 years of experience in the pharmaceutical industry, including leadership in global business development and corporate partnerships. The company also announced that Bryan Baldasare will not stand for re-election at the upcoming Annual General Meeting in December 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile  on October 16, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL1wKtpy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2575295519","title":"InMed Pharmaceuticals Appoints Neil Klompas to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2575295519","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575295519?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:01","pubTimestamp":1760436093,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has announced the appointment of Neil Klompas, CPA, CA, to its Board of Directors. Klompas brings over 30 years of experience in healthcare and biotechnology, including key leadership roles at Zymeworks Inc. He currently serves as CEO of Augerex Life Science Corp and holds board positions at NervGen Pharma and HTuO Biosciences.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL4KNXB9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INM","BK4007","ZYME"],"gpt_icon":0},{"id":"2569790783","title":"InMed Pharmaceuticals Reports Fiscal 2025 Results: Sales Increase 8% to $4.9M, Net Loss Widens to $8.2M","url":"https://stock-news.laohu8.com/highlight/detail?id=2569790783","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569790783?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:31","pubTimestamp":1758630671,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Inc. has announced its financial results for the fiscal year ending June 30, 2025. The company reported sales of $4.9 million in its BayMedica segment, marking an increase of $0.34 million, or 8%, compared to the previous year. The net loss for the company was recorded at $8.2 million, compared to a net loss of $7.7 million for the previous fiscal year. Research and development expenses decreased to $2.9 million from $3.2 million in the previous year, while general and administrative expenses increased to $6.6 million from $5.8 million. The company maintains a cash position of $11.1 million, which it expects will support its pharmaceutical developments into the fourth quarter of calendar year 2026. Additionally, InMed continued to advance its pharmaceutical pipeline, particularly with the INM-901 program, which targets multiple biological pathways related to Alzheimer's disease. The company also reported progress in the development of INM-089 for the treatment of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDLb2D81r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"gpt_icon":0},{"id":"2569790207","title":"InMed Pharmaceuticals FY Net Income USD -8.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2569790207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569790207?lang=en_us&edition=fundamental","pubTime":"2025-09-23 20:30","pubTimestamp":1758630623,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nPLX330770:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inmedpharma.com","stockEarnings":[{"period":"1week","weight":-0.0308},{"period":"1month","weight":-0.2342},{"period":"3month","weight":-0.3929},{"period":"6month","weight":-0.6222},{"period":"1year","weight":-0.7276},{"period":"ytd","weight":-0.1981}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.055524},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.102625},{"month":3,"riseRate":0.2,"avgChangeRate":-0.164852},{"month":4,"riseRate":0.6,"avgChangeRate":0.072322},{"month":5,"riseRate":0.4,"avgChangeRate":-0.055462},{"month":6,"riseRate":0.4,"avgChangeRate":-0.082897},{"month":7,"riseRate":0.2,"avgChangeRate":-0.134974},{"month":8,"riseRate":0.2,"avgChangeRate":0.013552},{"month":9,"riseRate":0.2,"avgChangeRate":-0.118637},{"month":10,"riseRate":0.2,"avgChangeRate":-0.198876},{"month":11,"riseRate":0.2,"avgChangeRate":-0.092328},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.132014}],"exchange":"NASDAQ","name":"InMed Pharmaceuticals Inc","nameEN":"InMed Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest InMed Pharmaceuticals Inc(INM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"InMed Pharmaceuticals Inc,INM,InMed Pharmaceuticals Inc股票,InMed Pharmaceuticals Inc股票老虎,InMed Pharmaceuticals Inc股票老虎国际,InMed Pharmaceuticals Inc行情,InMed Pharmaceuticals Inc股票行情,InMed Pharmaceuticals Inc股价,InMed Pharmaceuticals Inc股市,InMed Pharmaceuticals Inc股票价格,InMed Pharmaceuticals Inc股票交易,InMed Pharmaceuticals Inc股票购买,InMed Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest InMed Pharmaceuticals Inc(INM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction